Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain, Postoperative 4 Breast Neoplasms 4 Liver Neoplasms 2 Colonic Neoplasms 2 Chronic Pain 2 Carcinoma, Non-Small-Cell Lung 2 Supratentorial Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Postoperative Hemorrhage 1 Pilonidal Sinus 1 Pain 1 Oropharyngeal Neoplasms 1 Opioid-Related Disorders 1 Nevus, Pigmented 1 Neuroma 1 Neuralgia 1 Neoplasms 1 Melanoma 1 Malignant Pleural Neoplasm 1 Lung Neoplasms 1 Localised Prostate Cancer 1 Leiomyoma 1 Ileus 1 Hordeolum 1 Glioblastoma 1 Eyelid Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Lidocaine × 1 year × Clear all

NCT07347977 2026-01-16

LidCRM

First Affiliated Hospital of Ningbo University

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡